Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 673 matching trials from the live ClinicalTrials.gov search.
Conditions
Parkinson Disease, Parkinsonian Syndrome
Interventions
levodopa, Mirapex (pramipexole), [123I]ß-CIT and SPECT imaging
Drug · Procedure
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
30 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
13
States / cities
Oxnard, California • Englewood, Colorado • New Haven, Connecticut + 9 more
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study B

NCT01885559
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
486 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Conditions
Heart Failure
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
41
States / cities
Mobile, Alabama • Saraland, Alabama • Huntington Beach, California + 37 more
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
5,993 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
95
States / cities
Anniston, Alabama • Birmingham, Alabama • Jasper, Alabama + 82 more
Conditions
Asthma
Interventions
tiotropium 5mcg/day, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
18
States / cities
Fountain Valley, California • Fresno, California • Stockton, California + 15 more
Conditions
Diabetes Mellitus, Type 2
Interventions
BI 10773, Metformin, Sitagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
12
States / cities
Mission Viejo, California • Spring Valley, California • Walnut Creek, California + 9 more
Completed No phase listed Observational Accepts healthy volunteers

fMRI in Impulsivity

NCT02755181
Conditions
Impulse Control Disorders, Borderline Personality Disorder
Interventions
Experimental
Behavioral
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
3 Months to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • New Haven, Connecticut + 7 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Linagliptin
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 79 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
29
States / cities
Escondido, California • Greenbrae, California • Los Angeles, California + 25 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
62,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Terminated No phase listed Observational Results available

Natural History of Netherton Syndrome

NCT05902663
Conditions
Netherton Syndrome
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
Not listed
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Chicago, Illinois • Philadelphia, Pennsylvania
Conditions
Fibrosing Interstitial Lung Disease
Interventions
Nerandomilast, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Conditions
Heart Failure, Type 2 Diabetes, Chronic Kidney Diseases
Interventions
Virtual Consult Intervention
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Terminated Phase 2Phase 3 Interventional Results available

Nintedanib (BIBF 1120) in Mesothelioma

NCT01907100
Conditions
Mesothelioma
Interventions
Nintedanib, Pemetrexed, Cisplatin, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
545 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Littleton, Colorado + 7 more
Completed No phase listed Observational Results available

Real World Data on Management of Male LUTS

NCT03075449
Conditions
Benign Prostatic Hyperplasia
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Heart Failure with Preserved Ejection Fraction, Heart Failure, Diastolic, Diabetes Mellitus
Interventions
Empagliflozin 10 MG
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Dallas, Texas
Conditions
Breast Neoplasms
Interventions
Xentuzumab, Placebo, Everolimus, Exemestane
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
16
States / cities
Chandler, Arizona • Goodyear, Arizona • Beverly Hills, California + 13 more
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Nintedanib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
66 Years and older
Enrollment
1,798 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Milton, Massachusetts
Conditions
Diabetic Nephropathies, Diabetic Glomerulosclerosis
Interventions
There is no intervention
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
17
States / cities
Little Rock, Arkansas • Los Angeles, California • Palo Alto, California + 13 more
Conditions
Healthy, Hepatic Impairment
Interventions
BI 1291583
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
4
States / cities
Rialto, California • Orlando, Florida • Houston, Texas + 1 more
Conditions
Bronchiectasis
Interventions
BI 1291583, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 85 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
16
States / cities
Peoria, Arizona • Newport Beach, California • Sacramento, California + 12 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
afatinib, erlotinib
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
33
States / cities
Chandler, Arizona • La Jolla, California • Sacramento, California + 27 more
Conditions
Neoplasms
Interventions
BI 905681
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Sarasota, Florida • Philadelphia, Pennsylvania • Nashville, Tennessee
Conditions
Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease
Interventions
Survodutide, Placebo matching survodutide
Combination Product
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Peoria, Arizona • Los Angeles, California • Oxnard, California + 10 more